Cell custody and transportation servicesExtraction, purification, processing, storage, testing, and sale of tissue-derived componentsResearch, development, and dissemination of new therapies using cellsResearch, development, manufacturing, wholesale, and sale of pharmaceuticals and medical devicesOperation and management of medical facilitiesReal estate leasing and management servicesInformation processing, provision, and other information services, advertisingStem cell researchCell processing and storage servicesClinical research for autism spectrum disorderDevelopment of eye disease treatments using mesenchymal stem cell-derived conditioned mediumUmbilical cord blood family bank (HOPECELL)Research collaboration with universities
Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
58 EVENTS
Since its establishment in 1999, our company has been a pioneer of private umbilical cord blood banks, focusing on regenerative medicine and cell therapy, and has been engaged in the isolation and storage of umbilical cord blood-derived stem cells and related research and development.
Established Stem Cell Research Institute Inc. in Minato-ku, Tokyo
Established Stem Cell Research Institute Co., Ltd.
First stored umbilical cord blood at our company
Opened Osaka office as a Kinki region branch
Opened Fukuoka office as a Kyushu region branch
Opened Nagoya office as a Tokai region branch
Moved headquarters and cell processing center to current headquarters location (Minato-ku, Tokyo) due to increased sample volume
Relocated cell storage center to Yokohama, Kanagawa Prefecture to enhance storage capacity
Umbilical cord blood stored by our company in Kobe City, Hyogo Prefecture is used for leukemia transplantation therapy.
Umbilical cord blood stored by our company at Duke University in the United States is used for regenerative medicine for neurological disorders.
ISO 9001 certification obtained at the cell processing center in Minato-ku, Tokyo.
The field of regenerative medicine has been strongly promoted as a national policy toward its practical application, and in 2013, a law was enacted to enable citizens to receive regenerative medicine quickly and safely.
In 2013, a law was enacted to enable citizens to receive regenerative medicine quickly and safely.
Japan Trim Co., Ltd. (Tokyo Stock Exchange First Section) acquired 50.1% of our company's shares.
In 2014, the "Regenerative Medicine etc. Safety Assurance Act" was enacted to promote comprehensive advancement from research and development to commercialization. It enabled external outsourcing of cell processing to private companies like ours, which have obtained national approval (specific cell processing product manufacturing license), thereby establishing new pathways for applying umbilical cord blood to regenerative medicine.
Obtained a license for manufacturing specified cell processing products under the Regenerative Medicine Safety Assurance Act at the cell processing center in Minato-ku, Tokyo.
Entered into a contract for manufacturing specified cell processing products for the 'Regenerative Medicine Provision Plan for Pediatric Cerebral Palsy and Related Conditions' conducted by Kochi University Hospital.
Submitted a notification of umbilical cord blood handling business to the Health Bureau of the Ministry of Health, Labour and Welfare.
Initiated a joint research project with the Institute of Medical Science, University of Tokyo on 'Technology Development and Storage System Construction for Clinical Applications of Umbilical Cord.'
Obtained certification from the American Association of Blood Banks (AABB).
Opened a Toranomon office in Minato-ku, Tokyo, as a base for the management headquarters and comprehensive planning headquarters.
Signed a joint research agreement with the Institute of Medical Science and the University of Tokyo Hospital for research using autologous umbilical cord-derived cells.
Entered into a joint research agreement with the Institute of Medical Science, University of Tokyo, and the University of Tokyo Hospital, focusing on "Technology development and banking system construction for clinical application of perinatal accessory-derived cells" and "Research and development of tissue engineering using autologous umbilical cord-derived cells."
Entered into a contract for manufacturing specified cell processing products for clinical research conducted by Kochi University Hospital.
Signed a specific cell processing product manufacturing outsourcing contract for the clinical studies on "Allogeneic umbilical cord blood mononuclear cell transfusion for pediatric cerebral palsy and other brain disorders" and "Allogeneic umbilical cord blood nucleated cell transfusion for pediatric cerebral palsy and other brain disorders" conducted by the Kochi University School of Medicine Hospital.
Entered into a joint research agreement with Osaka University Graduate School of Medicine on "Development research of new meniscus regenerative medicine using umbilical cord tissue-derived stem cells and meniscus repair material."
Signed a contract for manufacturing specified cell processing products for clinical research led by a research group centered on Osaka City University.
In the phase II multicenter clinical trial of "autologous umbilical cord blood therapy for hypoxic-ischemic encephalopathy (HIE)" led by a research group centered on Osaka City University (now Osaka Prefecture University), a contract for the manufacturing of a specified cell product (autologous umbilical cord blood cell conditioning solution) was signed.
A joint research agreement was signed with Keio University School of Medicine on "cell therapy for perinatal brain injury using human amniotic fluid stem cells".
Opened a new cell processing center (Yokohama CPC) in Yokohama City, Kanagawa Prefecture.
Obtained a license for manufacturing specified cell processing products under the Regenerative Medicine Safety Assurance Act at the Yokohama cell processing center.
Obtained a manufacturing license for specified cell products under the Regenerative Medicine Safety Assurance Act at a cell processing center in Yokohama City, Kanagawa Prefecture.
Since April 2021, the storage service for "sai-bai" (umbilical cord blood), which has attracted global attention in the field of regenerative medicine, began for the first time in Japan under a technology license from the University of Tokyo.
Established a new cell storage center in Yokohama City, Kanagawa Prefecture, to increase storage capacity.
Listed shares on the Tokyo Stock Exchange Mothers market.
Joined the General Incorporated Association New Economic Federation (New Economic League).
Transitioned to the Tokyo Stock Exchange Growth market due to a review of market classifications.
Established a joint research course "Course on Musculoskeletal Sports Biomechanics" at Osaka University Graduate School of Medicine.
Relocated headquarters to Takanomō, Minato-ku, Tokyo.
Opened a Yokohama office in Yokohama City, Kanagawa Prefecture.
Signed a researcher-led clinical research contract with Osaka Public University on "Development of a treatment using autologous umbilical cord blood nucleated cells for autism spectrum disorder."
Launched a stem cell culture supernatant manufacturing service from umbilical cord blood.
Hosted a classical concert aimed at contributing to the SDGs.
Held a 25th anniversary celebration party.
Information on the researcher-led clinical research "Development of a treatment using autologous umbilical cord blood nucleated cells for autism spectrum disorder" was published on the Clinical Research Submission and Publication System (jRCT).
Launched the new brand "Umbilical Cord and Umbilical Cord Blood Family Bank HOPECELL."
Established the regional management company STEMCELL INNOVATIONS PTE. LTD. in Singapore.
Purchased land in Yokohama City, Kanagawa Prefecture, and prepared to open a new cell processing and storage center.
Purchased land in Yokohama City, Kanagawa Prefecture, for the establishment of a new cell processing and storage center.
Established a third cell storage center in Yokohama City, Kanagawa Prefecture.
Established the third cell storage center, the third facility, in Yokohama City, Kanagawa Prefecture.
Signed a joint venture agreement with the founding family office of Indonesia's largest conglomerate to expand cell bank operations in Southeast Asia.
Signed a joint venture agreement with the founding family office of Indonesia's largest conglomerate (a conglomerate) to expand cell bank operations in Southeast Asia.
Signed a joint research agreement with iPS Portal Inc. regarding a family iPS cell banking service derived from umbilical cord blood.
Signed a joint research agreement with the School of International Medical Welfare University, Department of Ophthalmology, and the Medical Corporation Seiwa with the aim of developing new eye disease treatments using conditioned medium derived from umbilical cord mesenchymal cells.
Completed a cell processing center and cell storage center in Singapore.
§07
News
29 ARTICLES
Exhibition at Two Maternal Events in November
Stem Cell Research Institute will exhibit at two maternity and family-oriented events held in Tokyo in November 2026. In addition to a booth guiding the storage of umbilical cord and cord blood, seminars on childbirth preparation by midwives will be conducted, and special benefits will be available exclusively for those who request materials during the event period. The Maternal Family Festival on November 8 will be held at T-CAT Hall within Tokyo City Air Terminal.
Free Webinar: Cord Blood and Blood Storage Facility Tour
Stem Cell Research Institute Inc. will hold a free online webinar on Friday, November 27, 2026, introducing basic knowledge of cord blood and cord blood stem cells and the latest research trends. The webinar will feature a live broadcast of the storage facility and will address participants' questions.
Free 11/27 Saibai & Blood LIVE Tour Webinar
On Friday, November 27, Stem Cell Research Institute will hold a free online webinar introducing basic knowledge and latest research trends on Saibai and blood. Additionally, a live tour of storage facilities will be broadcast from Yokohama's cell processing center and cell storage center, followed by a Q&A session.
Collaboration on R&D of Periosteum-Derived Extracellular Vesicles
Stem Cell Research Institute and Cell Source have signed a memorandum of understanding to promote the research and development of extracellular vesicles (including exosomes) secreted by periosteum-derived mesenchymal stromal cells. By combining both companies' periosteum and periosteal blood processing and storage technologies, cell processing, quality control, and knowledge of extracellular vesicles, they aim to build a technological foundation for utilization.
Completion of PHP Vulnerability Fix
The security patch for the PHP vulnerability disclosed on October 21, 2026, has been applied to our website. The website and all forms are available for use as usual.
Completion of Response to PHP Vulnerability
Following the PHP vulnerability disclosed on October 21, 2026, we have completed applying a security patch to the PHP used on our website. Our website and various forms are now available as usual.
Stem Cell Research Institute to Exhibit at Maternity Events
Stem Cell Research Institute will exhibit at maternity and family events in Ehime, Yokohama, and Osaka in October 2026. Staff will explain umbilical cord blood storage, and a benefit will be offered to visitors who request information. The event at Item Ehime will include activities for parents and children.
Stem Cell Institute to exhibit at September maternity events
Stem Cell Institute Co., Ltd. will exhibit at events for expectant parents and families in Tokyo and Nagano in September 2026, explaining umbilical cord and cord blood storage in accessible terms. Special benefits will be available to people requesting information during the events, and a seminar area on the second floor will provide information to know before childbirth.
Two Autumn Campaigns Begin
Stem Cell Research Institute Co., Ltd. is holding a limited-time early contract campaign from September 1 through November 30, 2026. Customers who sign a contract within 45 days of requesting information and complete storage will receive a digital gift based on their plan. The campaign is for people considering HOPECELL, a service that stores umbilical cords and cord blood collected at childbirth.
§08
Public records
GOV
National Tax Agency basic information8010401038548
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
株式会社ステムセル研究所
Trade name (kana)
ステムセルケンキュウジョ
Name in English
Corporation type
301
Address
〒105-0001 東京都港区虎ノ門１丁目２１番１９号
Postal code
1050001
Prefecture code
13
City code
103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2025-07-04
Change date
2023-06-08
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
1
Trade name image ID
Address image ID
Sequence number
2339506
METI gBizINFO8010401038548
Source: gBizINFO (Ministry of Economy, Trade and Industry)
